# Nomad Power Solutions, Inc.: overview NMAD · Nasdaq · CIK 1335105 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nmad.md) · [Financials](/companies/nmad/financials.md) · [Filings](/companies/nmad/filings.md) · [Insiders](/companies/nmad/insiders.md) Latest reported revenue: [$0](/filings/0001144204-14-017092.md) for Q4 FY2013, three months to 2013-12-31, from the 10-K filed Mar 21, 2014 (XBRL us-gaap:Revenues, accession 0001144204-14-017092). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.44)](/filings/0001493152-25-021941.md) | not reported | [(0.29)](/filings/0001493152-26-023150.md) | [(0.29)](/filings/0001493152-26-038001.md) | [(0.33)](/filings/0001493152-25-021941.md) | not reported | [(0.18)](/filings/0001493152-26-023150.md) | [(0.16)](/filings/0001493152-26-038001.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Net income: us-gaap:ProfitLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.50)](/filings/0001493152-22-007327.md) | [(3.99)](/filings/0001493152-24-010427.md) | [(2.66)](/filings/0001641172-25-000208.md) | [(1.59)](/filings/0001493152-26-014052.md) | [(1.26)](/filings/0001493152-26-014052.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nmad/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Legacy Wealth Managment, LLC/ID](/funds/2045082.md) | 2026-06-30 | $4.5m | 600,669 | | New +600,669 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.1m | 555,476 | | Added +505,997 | | [SCOTIA CAPITAL INC.](/funds/1335644.md) | 2026-06-30 | $2.1m | 283,162 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.1m | 143,036 | | Added +84,184 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $563.6k | 75,958 | | New +75,958 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $557.2k | 75,096 | | Added +57,700 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $499.2k | 67,280 | | Added +32,246 | | [Federation des caisses Desjardins du Quebec](/funds/2022297.md) | 2026-06-30 | $282.9k | 38,130 | | Reduced −26,357 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $205.2k | 27,655 | | New +27,655 | | [AXXCESS WEALTH MANAGEMENT, LLC](/funds/1911056.md) | 2026-06-30 | $102.2k | 13,771 | | New +13,771 | ## Recent filings [All 463 filings](/companies/nmad/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-06 | 16:18 ET | [8-K](/filings/0001493152-26-045896.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-045896 | | 2026-09-30 | 20:06 ET | [8-K](/filings/0001493152-26-045104.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-045104 | | 2026-09-17 | 20:10 ET | [8-K/A](/filings/0001493152-26-043120.md) | 9.01 Financial statements and exhibits | 0001493152-26-043120 | | 2026-08-14 | 12:30 ET | [10-Q](/filings/0001493152-26-038001.md) | Quarterly report, period 2026-06-30 | 0001493152-26-038001 | | 2026-07-31 | 13:10 ET | [8-K](/filings/0001493152-26-035561.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-035561 | | 2026-07-27 | 12:30 ET | [DEF 14A](/filings/0001493152-26-034713.md) | Proxy statement, period 2026-07-27 | 0001493152-26-034713 | | 2026-07-10 | 15:43 ET | [8-K](/filings/0001493152-26-032802.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-032802 | | 2026-07-02 | 20:00 ET | [8-K](/filings/0001493152-26-031870.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-031870 | | 2026-06-18 | 20:00 ET | [8-K](/filings/0001493152-26-029308.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-029308 | | 2026-06-16 | 20:00 ET | [8-K](/filings/0001493152-26-028878.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-028878 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-014052.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1335105 - Tickers: NMAD - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.